(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.
Ovid Therapeutics's earnings in 2026 is -$24,167,000.On average, 12 Wall Street analysts forecast OVID's earnings for 2026 to be -$83,969,382, with the lowest OVID earnings forecast at -$89,624,577, and the highest OVID earnings forecast at -$78,388,843. On average, 11 Wall Street analysts forecast OVID's earnings for 2027 to be -$88,168,784, with the lowest OVID earnings forecast at -$104,257,161, and the highest OVID earnings forecast at -$68,590,237.
In 2028, OVID is forecast to generate -$105,041,049 in earnings, with the lowest earnings forecast at -$124,376,964 and the highest earnings forecast at -$70,549,959.